Ilana Fogelman

Dr. Ilana Fogelman is CEO of MiCure. She brings more than 30 years of experience in the development and due diligence of medical technologies (drugs, biologics and in-vitro diagnostics), including regulatory affairs (former FDA medical reviewer), clinical trial design and analysis, market research (former biotech equity analyst), and competitive Intelligence. Co-founder of C2N Diagnostics, a private company developing treatments and diagnostics for Alzheimer’s Disease (C2N launched the PrecivityADTM test, a blood test to aid in the diagnosis of Alzheimer’s). As the COO of LifeTech Research, a consulting firm providing fundamental research to financial institutions, she conducted In-depth due diligence of more than 250 disruptive medical technologies across multiple therapeutic areas.

Dr. Fogelman is originally from Brazil, where she obtained her M.D., followed by five years of training at Harvard where she obtained an MPH and completed two post-doctoral fellowships in HIV clinical trials and cellular immunology.